Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Tamoxifen is a common treatment for advanced breast cancer.
• Flare hypercalcemia is a serious metabolic complication associated with tamoxifen therapy.
• Hypercalcemia in these patients is often linked to bone metastases.

Purpose of the Study:

• To investigate the incidence and characteristics of tamoxifen-induced flare hypercalcemia.
• To evaluate the efficacy of gallium nitrate in managing flare hypercalcemia.
• To determine if gallium nitrate allows for continued tamoxifen treatment.

Main Methods:

• Prospective monitoring of serum and urine calcium levels in hypercalcemic breast cancer patients receiving tamoxifen.
• Diagnosis of flare hypercalcemia based on pre-treatment calcium levels and timing of onset.
• Treatment of hypercalcemia with hydration and, for severe cases, gallium nitrate.

Main Results:

• 12 out of 93 patients developed flare hypercalcemia within weeks of starting tamoxifen.
• Hypercalcemia resolved upon tamoxifen withdrawal and recurred upon re-initiation.
• Gallium nitrate treatment (200 mg/m(2)/day for 5 days) normalized calcium levels in 6 patients, enabling continued tamoxifen therapy.

Conclusions:

• Tamoxifen-induced flare hypercalcemia is a significant iatrogenic complication in advanced breast cancer.
• Gallium nitrate is an effective antihypercalcemic agent for managing this condition.
• Gallium nitrate facilitates the safe continuation of tamoxifen therapy, preventing premature treatment discontinuation.